

NDA 206977/S-009

APPROVAL LETTER

Institut Biochimique SA c/o IBSA Pharma Inc. Attention: Christopher A. Jones, PhD Vice President, Scientific Affairs 1050 K Street NW, Suite 925 Washington, DC 20001

Dear Dr. Jones:

Please refer to your Supplemental New Drug Application (sNDA) dated and received April 1, 2020, and your amendments, pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for TIROSINT-SOL (levothyroxine sodium) oral solution.

We also refer to our approval letter dated January 13, 2021, which contained formatting errors in the content of labeling. This replacement approval letter incorporates the correction of these errors. The effective date will remain January 13, 2021, the date of the original approval letter.

We acknowledge receipt of your amendment dated September 25, 2020, which constituted a complete response to our June 5, 2020, action letter.

This Prior Approval supplemental new drug application provides for the addition of new dosage strengths (37.5  $\mu$ g/mL, 44  $\mu$ g/mL and 62.5  $\mu$ g/mL) of Tirosint-SOL and associated labeling changes.

## APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

## **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <a href="http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm">http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm</a>. Content of labeling must be identical to the enclosed labeling (text for the prescribing information) with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled *SPL Standard for Content of Labeling Technical Qs and As* at <a href="http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/GuidanceS/UCM072392.pdf">http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/GuidanceS/UCM072392.pdf</a>.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

## **CARTON AND CONTAINER LABELS**

Submit final printed carton and container labels that are identical to enclosed carton and container labels and carton and container labels submitted on September 25, 2020, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission "**Product Correspondence – Final Printed Carton and Container Labels for approved NDA 206977/S-009.**" Approval of this submission by FDA is not required before the labeling is used.

We remind you that you must comply with reporting requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Christopher LaFleur, Regulatory Business Process Manager, at (240) 402 - 4724.

Sincerely.


{See appended electronic signature page}

Ramesh Raghavachari, Ph.D.
Branch Chief, B1
Division of Post-Marketing Activities I
Office of Lifecycle Drug Products
Office of Pharmaceutical Quality
Center for Drug Evaluation and Research

Enclosure(s):

Content of Labeling Carton and Container Labeling

U.S. Food & Drug Administration Silver Spring, MD 20993 www.fda.gov



Digitally signed by Ramesh Raghavachari

Date: 1/26/2021 09:41:38PM

GUID: 502d0913000029f375128b0de8c50020